Further research has revealed that human CD8+ T cells derived from less differentiated subsets, such as TN cells [42, 43], exhibit superior traits with respect to adoptive immunotherapy; the anti-tumor capacities of CD8+ T cells derived from TCM subsets remain still controversial and poorly understood [43, 44]. The gene discussed is CD8A; the disease is neoplasm.